 KNOXVILLE, TN, March 23, 2021 GLOBE NEWSWIRE -- Provectus OTCQB: PVCT today announced that the United States Patent and Trademark Office USPTO has allowed US patent application 16412,872, which covers the use of intralesional aka intratumoral PV-10, an injectable formulation of Provectus proprietary small molecule rose bengal disodium RBD, as both a monotherapy and in combination with immune checkpoint blockade CB or radiotherapy for the treatment of relapsed and refractory pediatric solid tumor cancers. 